CHICAGO Thomson Financial - A cocktail of new anti-blood clot drug Prasugrel and aspirin reduces the risk of stent-related clots more than the standard treatment, according to a clinical trial review presented Saturday.
Prasugrel cut the risk of platelet formation around where a stent -- a small metal device -- was inserted to keep an artery open, by an average of 58 percent compared to Copidogrel (Plavix), according to analysis presented to the 57th annual American College of Cardiology conference in Chicago.
Researchers found that, during clinical trials, the anti-blood clot drug developed by Eli Lilly & Co and Daiichi Sankyo Co offered greater protection against the risk of stroke and death than Plavix, the standard treatment from Bristol-Myers Squibb and Sanofi-Aventis.
The results of the study, which involved 12,844 patients, are published in the online edition of Britain's The Lancet medical journal.
'Stent thrombosis was reduced both early (30 days) and late (450 days) after stent placement in patients randomly assigned Prasugrel,' said lead author Dr Stephen Wiviott, of Brigham and Women's Hospital and Harvard Medical School.
The patients involved in the trial had different types of heart stents, drug-coated or otherwise. Around half were treated with a combination of Prasugrel and aspirin, and the others with Plavix and aspirin.
Results of the trial, named TRITON-TIMI 38, were released last November and showed that Prasugrel was 19 percent more effective than Plavix in cutting the risk of strokes or heart attacks, although it provoked increased incidents of serious bleeding.
Prasugrel is a new molecule discovered by Daiichi Sankyo and developed in collaboration with Elli Lilly, which applied for US Food and Drug Administration (FDA) approval at the end of last year. If granted, it would be sold under the name Effient.
tf.TFN-Europe_newsdesk@thomson.com jlw COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2008 AFX News
